Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003

References

• Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal–infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. Paediatric AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173–80
   PubMed Web of Science ®Google Scholar
• CDC. Report of the NIH to define principles of the therapy of HIV infection. MMWR Recomm Rep 1998; 47(5)1–41
   Google Scholar
• Minkoff H, Augebraum M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997; 176: 478–89CDC
   PubMed Web of Science ®Google Scholar
• CDC. US Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 1998; 47(2)1–30
   Google Scholar
• Iribarren JA, Ramos JT, Guerra L, Coll O, De José MI, Domingo P, et al. Prevención de la transmisión vertical y tratamiento de la infección por VIH en la mujer embarazada. [Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman. Recommendations of the Study Group for AIDS, Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Association, the National AIDS Plan and the Spanish Gynecology and Obstetrics Society] (In Spanish). Enferm Infecc Microbiol Clin 2001; 19: 314–35
   PubMed Web of Science ®Google Scholar
• CDC. US Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 women infected for maternal health and Interventions to reduce perinatal HIV-1 transmission in the United States. November 17, 2005. Continually updated at: http://www.aidsinfo.nih.gov/guidelines/.
   Google Scholar
• Peña JM. Transmisión vertical del VIH-1. ¿Hasta dónde se puede reducir? [Vertical transmission of HIV-1. How much can we reduce it?] (in Spanish). Med Clin (Barc) 2000; 114: 297–8
   PubMed Web of Science ®Google Scholar
• Lorenzi P, Spicher VM, Laurebau B, Hirschel B, Kind C, Rudi C, et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. AIDS 1998; 12: F241–7
   PubMed Web of Science ®Google Scholar
• Pallardo F, Herranz L, Garcia-Ingelmo T, Grande C, Martin-Vaquero P, Jañez M, Gonzalez A. Early postpartum metabolic assessment in women with prior gestational diabetes. Diabetes Care 1999; 22: 1053–8
   PubMed Web of Science ®Google Scholar
• National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–57.
   PubMed Web of Science ®Google Scholar
• Diez JJ, Grande C, Pallardo LF, de la Morena ML, Ibars MT. Detección de la diabetes gestacional con la prueba de 50 gramos de glucosa: prevalencia y factores de riesgo. [Screening for gestational diabetes with the one hour 50 g glucose test: prevalence and relationship with risk factors] (in Spanish with English abstract). Med Clin (Barc) 1989; 93: 41–5
   PubMed Web of Science ®Google Scholar
• Bernardom M, Bernardom M, DeSeta F, Maso GP, Cescutti V, Olivuzzi M, et al. Pregnancy in HIV-positive women: 6 years of activity of the Regional Reference Center. Minerva Ginecol 2005; 57: 435–45
   PubMedGoogle Scholar
• Lehtovirta P, Skogberg K, Salo E, Ammala P, Ristola M, Suni J, et al. Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area. Acta Obstet Gynecol Scand 2005; 84: 945–50
   PubMed Web of Science ®Google Scholar
• Solis I, Muñoz E, Ramos JT, Gonzalez MI, Rojano X, Almeda J. Características maternas de una cohorte de gestantes con infección por el VIH-1. [Maternal characteristics of a cohort of pregnant women with HIV-1 infection] (in Spanish with English abstract). Med Clin (Barc) 2006; 127: 121–4
   PubMed Web of Science ®Google Scholar
• Sociedad Española Ginecología y Obstetricia. Base de datos perinatales 2002. (in Spanish). Available on WWW at: http://www.sego.es.
   Google Scholar
• Chmait R, Franklin P, Spector R, Hull AD. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370–3
   PubMedGoogle Scholar
• Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449–73
   PubMed Web of Science ®Google Scholar
• Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000; 25: 306–11
   PubMed Web of Science ®Google Scholar
• Tang JH, Sheffield JS, Grimes J, McElwee B, Roberts SC, Laibl V, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107: 1115–9
   PubMed Web of Science ®Google Scholar
• Watts H, Balasubramanian R, Maupin RT, Delke I, Dorembaum A, Fiore S, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190: 506–16
   PubMed Web of Science ®Google Scholar
• Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005; 19: 795–9
   PubMed Web of Science ®Google Scholar
• Beitune P, Duarte G, Foss MC, Montenegro RM, Spara P, Quintana SM, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006; 22: 59–63
   PubMed Web of Science ®Google Scholar
• Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy. Supplement: Safety & Toxicity. November 17, 2005. Continually updated at: http://www.aidsinfo.nih.gov/guidelines/.
   Google Scholar
• Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of Diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298–302
   PubMed Web of Science ®Google Scholar
• European Collaborative Study and Swiss Mother + Child Cohort Study. Combination therapy and duration of pregnancy. AIDS 2000; 14: 2913–20.
   Google Scholar
• Morris S, Dobles A, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 2005; 40: 30–3
   PubMed Web of Science ®Google Scholar
• Bellon JM, Sanchez-Ramón S, Ciria L, Leon JA, Gurbindo D, Fortuny C, et al. The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain. Med Sci Monit 2004; 10: CR179–84
   PubMed Web of Science ®Google Scholar
• Tuomala RE, Shapiro D, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of adverse outcome. N Engl J Med 2002; 346: 1863–70
   PubMed Web of Science ®Google Scholar